Siamab, BI Team To ‘Attack’ Potential Of Carbohydrate Antibodies In Cancer

With promising preclinical data for lead candidate ST1 in ovarian cancer, Siamab thinks therapeutics targeting tumor-associated carbohydrate antigens will offer potential in multiple solid tumor types.